Literature DB >> 33714274

Direct healthcare resource utilisation, health-related quality of life, and work productivity in patients with moderate rheumatoid arthritis: an observational study.

James Galloway1, Julie Edwards2, Shweta Bhagat3, Ben Parker4, Ai Lyn Tan5, James Maxwell6, Mike Wallington7, Sophee Blanthorn-Hazell8, Claire Bellamy9, Zoe Cole10.   

Abstract

BACKGROUND: The aim was to describe the population of patients with moderate rheumatoid arthritis (RA) in the United Kingdom and the burden of disease from the perspectives of the patient, caregiver, and health service.
METHODS: In this descriptive study, retrospective patient-level data were extracted from hospital medical records to assess healthcare resource utilisation and validated outcome measures were administered via questionnaire to patients with moderate RA (Disease Activity Score [DAS28] between 3.2 and 5.1) from eight secondary care centres, and their caregivers. Patient-reported outcome instruments were scored according to licensed manuals.
RESULTS: Outcome measures were completed by 102 patients and 38 caregivers. The mean EuroQoL-5 dimension-5 level crosswalk index value for patients was 0.62 (SD 0.24) compared to an England population norm of 0.82. Mean pain VAS score was 37.7 (SD 24.0) and mean Health Assessment Questionnaire Disability Index was 1.1 (SD 0.8). In employed patients who completed the Work Productivity and Activity Impairment questionnaire (n = 26), a mean 29% (SD 26%) reduction in work productivity was recorded. Patients experienced significant fatigue as a result of their RA (median Functional Assessment of Chronic Illness Therapy fatigue score 17.2 of a possible 52, interquartile range [IQR] 11.0-28.8). Over 50% of caregivers reported providing > 7 h of support care per week to the patient with RA, and 16 and 11% took paid/unpaid leave or reduced working hours, respectively. Mean Caregiver Reaction Assessment subscale scores were 1.9 (SD 0.9) for finance, 1.7 (SD 0.8) for health, 2.3 (SD 1.0) for schedule disruption, and 1.9 (SD 0.8) for family support. Patients had a mean 5.5 (SD 4.1) outpatient attendances and a median 9.0 (IQR 2.0-20.0) diagnostic and monitoring tests in the 12 months prior to enrolment.
CONCLUSIONS: This study shows that moderate RA has a considerable impact on healthcare resources and on patients' and caregivers' lives. There is scope to improve the management of patients with moderate RA.

Entities:  

Keywords:  Burden; Caregiver; DAS28; EQ-5D; Moderate; Patient-reported outcome; Quality of life; Resource utilisation; Rheumatoid arthritis

Mesh:

Year:  2021        PMID: 33714274      PMCID: PMC7956119          DOI: 10.1186/s12891-021-04110-1

Source DB:  PubMed          Journal:  BMC Musculoskelet Disord        ISSN: 1471-2474            Impact factor:   2.362


  41 in total

1.  Physical and psychosocial correlates of severe fatigue in rheumatoid arthritis.

Authors:  Dewy van Hoogmoed; Jaap Fransen; Gijs Bleijenberg; Piet van Riel
Journal:  Rheumatology (Oxford)       Date:  2010-03-29       Impact factor: 7.580

2.  Inequity in access to bDMARD care and how it influences disease outcomes across countries worldwide: results from the METEOR-registry.

Authors:  Sytske Anne Bergstra; Jaime C Branco; David Vega-Morales; Karen Salomon-Escoto; Nimmisha Govind; Cornelia F Allaart; Robert B M Landewé
Journal:  Ann Rheum Dis       Date:  2018-07-06       Impact factor: 19.103

3.  Benefit of biologics initiation in moderate versus severe rheumatoid arthritis: evidence from a United States registry.

Authors:  Arthur Kavanaugh; Edward Keystone; Jeffrey D Greenberg; George W Reed; Jenny M Griffith; Alan W Friedman; Katherine C Saunders; Arijit Ganguli
Journal:  Rheumatology (Oxford)       Date:  2017-07-01       Impact factor: 7.580

Review 4.  Systematic review of studies of productivity loss due to rheumatoid arthritis.

Authors:  Wayne Burton; Alan Morrison; Ross Maclean; Eric Ruderman
Journal:  Occup Med (Lond)       Date:  2005-11-11       Impact factor: 1.611

5.  Fatigue in cancer patients compared with fatigue in the general United States population.

Authors:  David Cella; Jin-Shei Lai; Chih-Hung Chang; Amy Peterman; Mitchell Slavin
Journal:  Cancer       Date:  2002-01-15       Impact factor: 6.860

6.  Impact of rheumatoid arthritis on quality of life, work productivity and resource utilisation: an observational, cross-sectional study in Brazil.

Authors:  Geraldo da Rocha Castelar Pinheiro; Rezaul K Khandker; Reiko Sato; Alison Rose; James Piercy
Journal:  Clin Exp Rheumatol       Date:  2013-01-16       Impact factor: 4.473

7.  Validity of the work productivity and activity impairment questionnaire--general health version in patients with rheumatoid arthritis.

Authors:  Wei Zhang; Nick Bansback; Annelies Boonen; Adam Young; Amitabh Singh; Aslam H Anis
Journal:  Arthritis Res Ther       Date:  2010-09-22       Impact factor: 5.156

8.  Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L).

Authors:  M Herdman; C Gudex; A Lloyd; Mf Janssen; P Kind; D Parkin; G Bonsel; X Badia
Journal:  Qual Life Res       Date:  2011-04-09       Impact factor: 4.147

9.  Measurement of patient outcome in arthritis.

Authors:  J F Fries; P Spitz; R G Kraines; H R Holman
Journal:  Arthritis Rheum       Date:  1980-02

10.  The outcome and cost-effectiveness of nurse-led care in the community for people with rheumatoid arthritis: a non-randomised pragmatic study.

Authors:  Richard A Watts; Janice Mooney; Garry Barton; Alex J MacGregor; Lee Shepstone; Lisa Irvine; David G I Scott
Journal:  BMJ Open       Date:  2015-08-25       Impact factor: 2.692

View more
  1 in total

1.  Predictive model to identify multiple failure to biological therapy in patients with rheumatoid arthritis.

Authors:  Marta Novella-Navarro; Diego Benavent; Virginia Ruiz-Esquide; Carolina Tornero; Mariana Díaz-Almirón; Chafik Alejandro Chacur; Diana Peiteado; Alejandro Villalba; Raimon Sanmartí; Chamaida Plasencia-Rodríguez; Alejandro Balsa
Journal:  Ther Adv Musculoskelet Dis       Date:  2022-10-06       Impact factor: 3.625

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.